TY - JOUR T1 - Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1069 LP - 1073 DO - 10.3899/jrheum.121427 VL - 40 IS - 7 AU - Luis Aguilar-Lozano AU - Jose Dionisio Castillo-Ortiz AU - Cesar Vargas-Serafin AU - Jorge Morales-Torres AU - Adriana Sanchez-Ortiz AU - Carlos Sandoval-Castro AU - Jorge Padilla-Ibarra AU - Claudia Hernandez-Cuevas AU - Cesar Ramos-Remus Y1 - 2013/07/01 UR - http://www.jrheum.org/content/40/7/1069.abstract N2 - Objective. Data on when to stop use of biological agents in rheumatoid arthritis (RA) are scant. We assessed the length of remission and the rate of clinical relapse in patients with RA who had to discontinue treatment with tocilizumab (TCZ) because of the ending of longterm (5 yrs) open-label clinical trials. Methods. All patients at 2 participating centers in Mexico were in remission, defined as Disease Activity Score 28 ≤ 2.6, with no swollen joints at the time of the last TCZ infusion. Patients were followed thereafter every 8 weeks for 12 months or until relapse. Relapse was defined as the presence of ≥ 1 swollen joint. Doses of methotrexate and antiinflammatory drugs were not changed during the followup period. Results. Forty-five patients were analyzed, 87% were women (mean age 52 yrs, mean disease duration 14 yrs). During the 12 months of followup, 44% of patients maintained remission. Relapses occurred in 56% of patients: 14 during the first 3 months after the last TCZ administration. Retreatment using other agents achieved low disease activity or remission. Conclusion. Longterm clinical remission is possible in a number of patients with RA after suspension of TCZ. This effect has also been reported with other biologic agents. Additional data are required to support recommendations for discontinuing a biological agent after achieving remission. ER -